Clinical Trials Directory

Trials / Completed

CompletedNCT02268032

Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

Assess the Effect of DHEA or Other Androgenic Agents on Ovarian Reserve Markers in Women With Diminished Ovarian Reserve

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
94 (actual)
Sponsor
Laboratorios Andromaco S.A. · Industry
Sex
Female
Age
38 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study was conducted to evaluate the effect of a continuous administration of dehydroepiandrosterone (DHEA) or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral follicle count (AFC) and anti-Müllerian hormone (AMH) concentrations.

Detailed description

Healthy women attending the clinic of the Mother and Health Research Institute (IDIMI) were invited to participate, if they could not become pregnant due to surgical sterilization, and if they presented no contraindications to use androgen therapy. Project Objectives : The general objective was to evaluate pharmacokinetic parameters of three vaginal rings containing DHEA, testosterone, or combination of both hormones in women. Secondary objectives were to assess effects on the hormonal profile, tolerability and incidence of adverse events. * DHEA and/or, testosterone levels * Estradiol, follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), androstenedione, morning cortisol, insulin growth factor 1 (IGF-1) levels * Tolerability and safety assessment by the use of the vaginal ring. * The incidence of adverse events

Conditions

Interventions

TypeNameDescription
DRUGDHEADHEA 2.2 g in vaginal ring
DRUGAnother Androgenic Agent (VRaA)Testosterone 35 mg in vaginal ring
DRUGFixed combination of 2 androgenic agents (VR2A)DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring

Timeline

Start date
2014-07-15
Primary completion
2016-08-31
Completion
2016-08-31
First posted
2014-10-20
Last updated
2019-05-29

Locations

1 site across 1 country: Chile

Source: ClinicalTrials.gov record NCT02268032. Inclusion in this directory is not an endorsement.